Treats migraine with or without aura. Sold as Imitrex, Tosymra. Every FDA application for this active ingredient: 2 branded and 5 generic.
As of Nov 13, 2026, FDA lists 7 applications for Sumatriptan (sold as Imitrex, Tosymra), first approved Aug 26, 1997, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2024 | Change | Beneficiaries |
|---|---|---|---|---|
| Sumatriptan Succinate | Part D | $38.0M | -30% | 479,118 |
| Sumatriptan | Part D | $8.5M | -21% | 14,863 |
| Imitrex | Part D | $5.1M | +0% | 803 |
| Zembrace Symtouch | Part D | $2.5M | -15% | 342 |
| Onzetra Xsail | Part D | $458K | -10% | 119 |
| Tosymra | Part D | $382K | -22% | 173 |
| Imitrex | Part D | $28K | -88% | 24 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Aug 26, 1997 | ImitrexNDA 20626 · New dosage form | Glaxosmithkline | 15 | Marketed |
| Feb 19, 2016 | SumatriptanANDA 204841 | Lannett Co Inc | 2 | Marketed |
| Jan 25, 2019 | TosymraNDA 210884 · New dosage form | Tonix Meds | 0 | Marketed |
| Sep 21, 2020 | SumatriptanANDA 213465 | Padagis Israel | 0 | Marketed |
| Sep 21, 2020 | SumatriptanANDA 213650 | Perrigo Uk Finco | 0 | Marketed |
| Feb 17, 2021 | SumatriptanANDA 208967 | Regcon Holdings | 0 | Marketed |
| Feb 22, 2021 | SumatriptanANDA 214209 | Cipla | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA
Glaxosmithkline
Cipla